Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07407582 | Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS) | PHASE2 | NOT YET_RECRUITING | 25 | — | — | Apr 30, 2026 | Apr 30, 2028 | Feb 12, 2026 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Pedmark® STS | DRUG | Pedmark® STS (20 g/m2) will be given via intravenous infusion over 15-30 minutes, starting 6 hours after the completion of cisplatin infusion. Pedmark® STS will be given each day of cisplatin infusion. |